Combination of p16INK4a/Ki67 immunocytology and hpv polymerase chain reaction for the noninvasive analysis of HPV involvement in head and neck cancer

Cancer Cytopathology

Volumn 123, Issue 4, 2015, Pages 219-229

  Linxweiler, Maximilian ^a   Bochen, Florian ^a   Wemmert, Silke ^a   Lerner, Cornelia ^a   Hasenfus, Andrea ^a   Bohle, Rainer Maria ^a   Al Kadah, Basel ^a   Takacs, Zoltan Ferenc ^a   Smola, Sigrun ^a   Schick, Bernhard ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

head and neck squamous cell carcinoma (HNSCC); human papillomavirus (HPV); liquid based cytology; p16INK4a Ki67 dual stain; prognostic and predictive biomarkers

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN; VIRUS DNA; TUMOR MARKER;

ADULT; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; FEASIBILITY STUDY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; MALE; NON INVASIVE MEASUREMENT; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; CARCINOMA, SQUAMOUS CELL; CASE CONTROL STUDY; COMPLICATION; DIAGNOSTIC USE; EVALUATION STUDY; GENETICS; HEAD AND NECK NEOPLASMS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; RISK FACTOR; VIROLOGY;

CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTODIAGNOSIS; DNA, VIRAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84937605438     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21512     Document Type: Article

References (43)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108.
2. Cooper JS, Porter K, Mallin K, et al., National Cancer Database report on cancer of the head and neck: 10-year update. Head Neck. 2009; 31: 748-758.
3. Barnes L, Eveson JW, Reichart P, Sidransky D,. Pathology and genetics of head and neck tumors. World Health Organization Classification of Tumors, IARC Press, Lyon, 2005.
4. Gillison ML, Koch WM, Capone RB, et al., Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000; 92: 709-720.
5. D' Souza G, Kreimer AR, Viscidi R, et al., Case-control study of human papillomavirus and oropharyngeal cancer. New Engl J Med. 2007; 356: 1944-1956.
6. Marklund L, Hammerstedt L,. Impact of HPV in oropharyngeal cancer. J Oncol. 2011: 509036.
7. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F,. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005; 6: 204.
8. Meurman JH,. Infectious and dietary risk factors of oral cancer. Oral Oncol. 2010; 46: 411-413.
9. Ang KK, Harris J, Wheeler R, et al., Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363: 24-35.
10. Tribius S, Ihloff AS, Rieckmann T, Petersen C, Hoffmann M,. Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know. Cancer Lett. 2011; 304: 71-79.
11. Fakhry C, Westra WH, Li S, et al., Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2007; 100: 261-269.
12. Holzinger D, Schmitt M, Dyckhoff G, Benner A, Pawlita M, Bosch FX,. Viral RNA patterns and high viral load reliably define oropharynx carcinomas with active HPV16 involvement. Cancer Res. 2012; 72: 4993-5003.
13. Umudum H, Rezanko T, Dag F, Dogruluk T,. Human papillomavirus genome detection by in situ hybridization in fine-needle aspirates of metastatic lesions from head and neck squamous cell carcinomas. Cancer. 2005; 105: 171-177.
14. Bishop JA, Maleki Z, Valsamakis A, et al., Application of the Hybrid Capture 2 assay to squamous cell carcinomas of the head and neck. Cancer Cytopathol. 2012; 120: 18-25.
15. Guo M, Khanna A, Dhillon J, et al., Cervista HPV assays for fine-needle aspiration specimens are a valid option for human papillomavirus testing in patients with oropharyngeal carcinoma. Cancer Cytopathol. 2014; 122: 96-103.
16. Abrahao AC, Bonelli BV, Nunes FD, Dias EP, Cabral MG,. Immunohistochemical expression of p53, p16 and hTERT in oral squamous cell carcinoma and potentially malignant disorders. Braz Oral Res. 2011; 25: 34-41.
17. Singhi AD, Westra WH,. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer. 2010; 116: 2166-2173.
18. Holzinger D, Flechtenmacher C, Henfling N, et al., Identification of oropharyngeal squamous cell carcinomas with active HPV16 involvement by immunohistochemical analysis of the retinoblastoma protein pathway. Int J Cancer. 2013; 133: 1389-1399.
19. Klussmann JP, Gültekin E, Weissenborn SJ, et al., Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol. 2003; 162: 747-753.
20. INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results. Gynecol Oncol. 2010; 119: 98-105.
21. Wentzensen N, von Knebel Doeberitz M,. Biomarkers in cervical cancer screening. Dis Markers. 2007; 23: 315-330.
22. INK4a: a reappraisal of its use in cervical biopsies. Pathology. 2008; 40: 335-344.
23. INK4a and Ki-67 predicts CIN2/3 and AIS/adenocarcinoma. Cancer Cytopathol. 2012; 120: 26-34.
24. INK4A, Ki-67, and human papillomavirus L1 capsid protein immunochemical staining on cell blocks from residual liquid-based gynecologic cytology specimens. Cancer Cytopathol. 2010; 118: 47-55.
25. Rietbergen MM, Snijders PJF, Beekzada D, et al., Molecular characterization of p16-immunopositive but HPV DNA-negative oropharyngeal carcinomas. Int J Cancer. 2014; 134: 2366-2372.
26. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T,. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol. 1998; 153: 1741-1748.
27. Pepe MS,. The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford, UK: Oxford University Press; 2003.
28. De Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ,. The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol. 1995; 76: 1057-1062.
29. Ruprecht K, Ferreira H, Flockerzi A, et al., Human endogenous retrovirus family HERV-K(HML-2) RNA transcripts are selectively packaged into retroviral particles produced by the human germ cell tumor line Tera-1 and originate mainly from a provirus on chromosome 22q11.21. J Virol. 2008; 82: 10008-10016.
30. Kasap B, Yetimalar H, Keklik A, Yildiz A, Cukurova K, Soylu F,. Prevalence and risk factors for human papillomavirus DNA in cervical cytology. Eur J Obstet Gynecol Reprod Biol. 2011; 159: 168-171.
31. Schmidt D, Bergeron C, Denton KJ, Ridder R,. p16/ki-67 Dual-stain cytology in the triage of ASCUS and LSIL Papanicolaou cytology: results from the European equivocal or mildly abnormal papanicolaou cytology study. Cancer Cytopathol. 2011; 119: 158-166.
32. INK4a/Ki67 co-expression specifically identifies transformed cells in the head and neck region. Int J Cancer. 2014 [Epub ahead of print].
33. Stoler MH, Schiffmann M,. Atypical Squamous Cell of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001; 285: 1500-1505.
34. Loghavi S, Walts AE, Bose S,. CINtec® PLUS Dual Immunostain: a triage tool for cervical pap smears with atypical squamous cells of undetermined significance and low grade squamous intraepithelial lesion. Diagn Cytopathol. 2013; 41: 582-587.
35. INK4a/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion. Cancer Cytopathol. 2013; 121: 136-145.
36. Rietbergen MM, Snijders PJ, Beekzada D, et al., Molecular characterization of p16-immunopositive but HPV DNA-negative oropharyngeal carcinomas. Int J Cancer. 2014; 134: 2366-2372.
37. Dragomir LP, Simionescu C, Margaritescu C, Stepan A, Dragomir IM, Popescu MR,. P53, p16 and Ki67 immunoexpression in oral squamous carcinomas. Rom J Morphol Embryol. 2012; 53: 89-93.
38. Motta Rda R, Zettler CG, Cambruzzi E, Jotz GP, Berni RB,. Ki-67 and p53 correlation prognostic value in squamous cell carcinomas of the oral cavity and tongue. Braz J Otorhinolaryngol. 2009; 75: 544-549.
39. Westra WH,. The changing face of head and neck cancer in the 21st century: the impact of HPV on the epidemiology and pathology of oral cancer. Head Neck Pathol. 2009; 3: 78-81.
40. Fakhry C, Rosenthal BT, Clark DP, Gillison ML,. Associations between oral HPV16 infection and cytopathology; evaluation of an oropharyngeal pap-test equivalent in high-risk populations. Cancer Prev Res. (Phila). 2011; 4: 1378-1384.
41. Remmerbach TW, Meyer-Erbrecht D, Aach T, et al., Toward a multimodal cell analysis of brush biopsies for the early detection of oral cancer. Cancer Cytopathol. 2009; 117: 228-235.
42. Remmerbach T, Weidenbach H, Pomjanski N, et al., Cytologica and DNA-cytometric early diagnosis of oral cancer. Anal Cell Pathol. 2001; 22: 211-221.
43. Pentenero M, Carrozzo M, Pagano M, et al., Oral mucosal dysplastic lesions and early squamous cell carcinomas: underdiagnosis from incisional biopsy. Oral Dis. 2003; 9: 68-72.